Kamada (KMDA) continues to expect to generate fiscal year 2025 total revenues in the range of $178 million to $182 million, and adjusted EBITDA in the range of $38 million to $42 million, representing a year-over-year increase of approximately 12% in revenues and 17% in adjusted EBITDA based on the mid-point of the 2025 guidance.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KMDA:
- Kamada board declares special dividend of 20c per share
- Kamada to Release Q4 and Fiscal Year 2024 Financial Results
- KMDA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Kamada Secures $25 Million Contract for Immune Globulin Products in Latin America
- Kamada awarded $25M 3-year contract to supply kamrab, varizig in Latin America